Your browser doesn't support javascript.
loading
Predicting continuous amyloid PET values with CSF and plasma Aß42/Aß40.
Wisch, Julie K; Gordon, Brian A; Boerwinkle, Anna H; Luckett, Patrick H; Bollinger, James G; Ovod, Vitaliy; Li, Yan; Henson, Rachel L; West, Tim; Meyer, Mathew R; Kirmess, Kristopher M; Benzinger, Tammie L S; Fagan, Anne M; Morris, John C; Bateman, Randall J; Ances, Beau M; Schindler, Suzanne E.
Afiliação
  • Wisch JK; Department of Neurology Washington University in Saint Louis St. Louis Missouri USA.
  • Gordon BA; Department of Radiology Washington University in Saint Louis St. Louis Missouri USA.
  • Boerwinkle AH; Hope Center Washington University in Saint Louis St. Louis Missouri USA.
  • Luckett PH; Knight Alzheimer Disease Research Center Washington University School of Medicine St Louis Missouri USA.
  • Bollinger JG; Department of Neurology Washington University in Saint Louis St. Louis Missouri USA.
  • Ovod V; Department of Neurology Washington University in Saint Louis St. Louis Missouri USA.
  • Li Y; Department of Neurology Washington University in Saint Louis St. Louis Missouri USA.
  • Henson RL; The Tracy Family SILQ Center for Neurodegenerative Biology St. Louis Missouri USA.
  • West T; Department of Neurology Washington University in Saint Louis St. Louis Missouri USA.
  • Meyer MR; The Tracy Family SILQ Center for Neurodegenerative Biology St. Louis Missouri USA.
  • Kirmess KM; Department of Radiology Washington University in Saint Louis St. Louis Missouri USA.
  • Benzinger TLS; Department of Neurology Washington University in Saint Louis St. Louis Missouri USA.
  • Fagan AM; C2N Diagnostics St. Louis Missouri USA.
  • Morris JC; C2N Diagnostics St. Louis Missouri USA.
  • Bateman RJ; C2N Diagnostics St. Louis Missouri USA.
  • Ances BM; Department of Radiology Washington University in Saint Louis St. Louis Missouri USA.
  • Schindler SE; Knight Alzheimer Disease Research Center Washington University School of Medicine St Louis Missouri USA.
Alzheimers Dement (Amst) ; 15(1): e12405, 2023.
Article em En | MEDLINE | ID: mdl-36874595
Introduction: Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid beta (Aß)42/Aß40 could predict continuous values for amyloid PET. Methods: CSF Aß42 and Aß40 were measured with automated immunoassays. Plasma Aß42 and Aß40 were measured with an immunoprecipitation-mass spectrometry assay. Amyloid PET was performed with Pittsburgh compound B (PiB). The continuous relationships of CSF and plasma Aß42/Aß40 with amyloid PET burden were modeled. Results: Most participants were cognitively normal (427 of 491 [87%]) and the mean age was 69.0 ± 8.8 years. CSF Aß42/Aß40 predicted amyloid PET burden until a relatively high level of amyloid accumulation (69.8 Centiloids), whereas plasma Aß42/Aß40 predicted amyloid PET burden until a lower level (33.4 Centiloids). Discussion: CSF Aß42/Aß40 predicts the continuous level of amyloid plaque burden over a wider range than plasma Aß42/Aß40 and may be useful in AD staging. Highlights: Cerebrospinal fluid (CSF) amyloid beta (Aß)42/Aß40 predicts continuous amyloid positron emission tomography (PET) values up to a relatively high burden.Plasma Aß42/Aß40 is a comparatively dichotomous measure of brain amyloidosis.Models can predict regional amyloid PET burden based on CSF Aß42/Aß40.CSF Aß42/Aß40 may be useful in staging AD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article